Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab
Authors:
- A. J. Grillo-LópezAGA. J. Grillo-López
- B. AlkuzwenyBAB. Alkuzweny
- R. WeaverRWR. Weaver
- A. LaroccaALA. Larocca
- P. MclaughlinPMP. Mclaughlin
- 1 January 2006
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 47 (9) , 1830-1840
Abstract
Several factors predict outcome for patients with non-Hodgkin's lymphoma (NHL) after chemotherapy. However, predictors of response to rituximab have not been identified. Baseline characteristics for 166 NHL patients (130 follicular) in a phase III trial of rituximab were analysed by univariate and multivariate methods to determine whether any of 27 factors predict response and/or response duration. In a univariate analysis, response to rituximab was associated with follicular histology, no prior fludarabine therapy, prior autologous bone marrow transplantation (ABMT), lack of bone marrow involvement or extranodal disease, positive bcl-2 in blood, and fewer relapses. By univariate analysis, longer median time to progression (TTP) and/or duration of response (DR) after rituximab therapy was associated with International Prognostic Index lower-risk group, multiagent chemotherapy, and low/normal serum lactate dehydrogenase (LDH) or beta2 microglobulin. In the multivariate analysis, response to rituximab correlated with follicular histology, prior ABMT, multiagent chemotherapy, and no bone marrow involvement; longer TTP and/or DR correlated with low/normal serum LDH or beta2 microglobulin, high CD3+ cells, and response to last chemotherapy. The follicular lymphoma international prognostic index (FLIPI) did not correlate consistently with response to rituximab or response duration. Several factors associated with prognosis following chemotherapy did not correlate with response to rituximab or response duration. NHL patients can respond to rituximab despite having factors associated with a poor outcome to chemotherapy.Keywords
This publication has 34 references indexed in Scilit:
- CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood, 2005
- Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-UpJournal of Clinical Oncology, 2004
- Follicular Lymphoma International Prognostic IndexBlood, 2004
- Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationBlood, 2001
- Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage 111-IV patientsAnnals of Oncology, 1997
- Presenting features, natural history, and prognostic factors in localized non‐Hodgkin's lymphomas: analysis of 117 cases from a single institutionEuropean Journal of Haematology, 1995
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Follicular lymphomas: Assessment of prognostic factors in 127 patients followed for 10 yearsAnnals of Oncology, 1991
- Distinctive Chromosomal Abnormalities in Histologic Subtypes of Non-Hodgkin's LymphomaNew England Journal of Medicine, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958